| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2022-07-19 |
| タイトル |
|
|
タイトル |
Understanding In Vivo Fate of Nucleic Acid and Gene Medicines for the Rational Design of Drugs |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Fumoto, Shintaro
Yamamoto, Tsuyoshi
Okami, Kazuya
Maemura, Yuina
Terada, Chisato
Yamayoshi, Asako
Nishida, Koyo
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Nucleic acid and genetic medicines are increasingly being developed, owing to their potential to treat a variety of intractable diseases. A comprehensive understanding of the in vivo fate of these agents is vital for the rational design, discovery, and fast and straightforward development of the drugs. In case of intravascular administration of nucleic acids and genetic medicines, interaction with blood components, especially plasma proteins, is unavoidable. However, on the flip side, such interaction can be utilized wisely to manipulate the pharmacokinetics of the agents. In other words, plasma protein binding can help in suppressing the elimination of nucleic acids from the blood stream and deliver naked oligonucleotides and gene carriers into target cells. To control the distribution of these agents in the body, the ligand conjugation method is widely applied. It is also important to understand intracellular localization. In this context, endocytosis pathway, endosomal escape, and nuclear transport should be considered and discussed. Encapsulated nucleic acids and genes must be dissociated from the carriers to exert their activity. In this review, we summarize the in vivo fate of nucleic acid and gene medicines and provide guidelines for the rational design of drugs. |
| 書誌情報 |
Pharmaceutics
巻 13,
号 2,
p. 159,
発行日 2021-01-26
|
| 出版者 |
|
|
出版者 |
MDPI |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1999-4923 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.3390/pharmaceutics13020159 |
| 権利 |
|
|
権利情報 |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Pharmaceutics, 13(2), art. no. 159; 2021 |
P13_159.pdf (2.9 MB)
